End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

@article{Scher2011EndPA,
  title={End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.},
  author={Howard I. Scher and Michael J Morris and Ethan Basch and Glenn Heller},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 27},
  pages={3695-704}
}
New therapeutic approaches for castration-resistant prostate cancer (CRPC) introduce new treatment dilemmas: how best to sequence these options to maximally benefit patients, what tests to perform before and after treatment to assess disease status, and how to interpret the test results and use them to guide treatment. New and specific end points for… CONTINUE READING